STOCK MARKET BSE NSE

'Drug pricing policy, regulations slowing down pharma growth'

The new drug pricing policy and tightened regulatory environment have collectively dragged down the growth of Indian pharmaecutical market to single digit at 9.8 per cent in financial year 2012-13 as against a healthy 16.6 per cent a year ago.

Published: 01st November 2013 09:24 AM  |   Last Updated: 01st November 2013 09:24 AM   |  A+A-

The new drug pricing policy and tightened regulatory environment have collectively dragged down the growth of Indian pharmaecutical market to single digit at 9.8 per cent in financial year 2012-13 as against a healthy 16.6 per cent a year ago.

The joint report by CII-PwC titled ‘India Pharma Inc: Changing Landscape of Indian Pharma Industry’, also said challenges such as delays in clinical trial approvals, uncertainities over the FDI policy, a uniform code for sales and marketing practices and compulsory licensing are plaguing the industry's growth.

“Though the market value has seen an increase, the sector overall has experienced a slowdown with its growth going down to 9.8 per cent from 16.6 per cent in 2012,” it said adding that the implementation of the National Pharmaceutical Pricing Policy 2012 by the government eroded margins from 20 per cent and 10 per cent to 16 per cent and 8 per cent for retailers and stockists respectively.

“This decrease in the stockist margins led to a significant uncertainty among many stockists regarding the feasibility of staying in business due to lower profitability post the margin reduction,” it said.

In the light of pharma companies like Ranbaxy Laboratories and Wockhardt coming under the US FDA scanner, the report said Indian firms sould step up their compliance to US FDA regulations as they drive their major share of exports from the US market.

“The sector is currently experiencing slow growth. Henceforth, both the Indian and foreign companies operating in India will have to device suitable strategies in order to be in the top 10 global markets by 2020,” Rajiv Modi, Chairman, CII Pharma Summit 2013.

According to Sujay Shetty, PwC India Leader (pharma & life sceinces) the economic environment in India is tougher now than ever before. “While pharma companies focus their attention on measures to combat the growth slowdown, they will need to work with the government and other stakeholders to discuss and resolve regulatory challenges,” he said.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp